From Lab To Tox Batch: A First-Time-Right API Scale-Up

This case study explores the development and scale-up of a novel small-molecule therapy for vascular calcification disorders, with a focus on establishing a robust, first-time-right manufacturing process. The initial synthesis posed several challenges, including low yields, limited intermediate stability, and complex phosphorylation chemistry.

Further complexity arose from difficult intermediate isolation steps, sensitivity to reactive conditions, and the need to maintain strict process safety during scale-up. To overcome these hurdles, a systematic, science-led approach was applied, combining mechanistic understanding with targeted process optimization, guided by safety, environmental, and efficiency considerations.

Key refinements included improved reaction control, optimized reagent addition strategies, and enhanced purification techniques, collectively delivering higher yields and a cleaner impurity profile. As a result, the process was successfully transitioned from laboratory development to kilogram-scale manufacturing, producing high-purity material suitable for toxicology studies and continued clinical advancement.

Explore how integrated process design and optimization can help accelerate complex molecule development while ensuring scalability, safety, and quality.